French Project to Tackle Antibiotic Resistance with Biotech and Economics

A team of French organizations led by the biotech firm Antabio has launched a €17M project to deploy therapeutic, diagnostic, and economic innovations in the battle against antibiotic resistance.

The project, dubbed ARPEGE, involves four partners covering a variety of disciplines: the antibiotics developer Antabio; the diagnostics heavyweight bioMérieux; the university hospital group Hospices Civils de Lyon (HCL) paired with the International Centre for Infectious Disease Research; and the Toulouse School of Economics (TSE). The total budget of the four-year project is expected to be €17M, with almost €9M already provided by the French government.

The Covid-19 pandemic has shone a spotlight on the importance of treatments for infectious diseases. As innovations and investments are mobilized to fight the virus, antibiotic resistance is gaining recognition as a major threat. 

As we face a historic pandemic, ARPEGE is creating the synergies needed for a coordinated and effective French response to another imminent global challenge: antibiotic resistance,” said Marc Lemonnier, CEO of Antabio,

The post French Project to Tackle Antibiotic Resistance with Biotech and Economics appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Source

About the Author: Biotech Today

You might like